Fusion proteins with immunoglobulin portions, the preparation and use thereof

• US 20030064480A1
• Filed: 04/30/2002
• Published: 04/03/2003
• Est. Priority Date: 06/28/1990
• Status: Abandoned Application

• Current Assignee: Sanofi-Aventis Deutschland GmbH (Sanofi )
• Original Assignee: Sanofi-Aventis Deutschland GmbH (Sanofi )
• Inventors: Oquendo, Patricia, Zettlmeissl, Gerd, Lauffer, Leander, Seed, Brian
• Application Number:
  US10/135,747
• Publication Number:
  US 20030064480A1
• Time in Patent Office: Days
• US Class Current: 435/69.7
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: C07K 14/505 Erythropoietin [EPO]
• CPC Class Codes: C07K 14/7155 for interleukins [IL]
• CPC Class Codes: C07K 14/745 Blood coagulation or fibrinolysis factors
• CPC Class Codes: C07K 16/00 Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies antibodies with enzymatic activity, e.g. abzymes C12N9/0002
• CPC Class Codes: C07K 2319/00 Fusion polypeptide

Abstract

The invention relates to genetically engineered soluble fusion proteins composed of human proteins not belonging to the immunoglobulin family, or of parts thereof, and of various portions of the constant region of immunoglobulin molecules. The functional properties of the two fusion partners are surprisingly retained in the fusion protein.

Claims

1. A soluble fusion protein composed of human proteins not belonging to the immunoglobulin family, or of parts thereof, and of various portions of immunoglobulin molecules of all subclasses.

2. A fusion protein as claimed in claim 1, wherein the immunoglobulin portion is the constant part of the heavy chain of human IgG.

3. A fusion protein as claimed in claim 2, wherein the immunoglobulin portion is the constant part of the heavy chain of human IgG1 or a protein A-binding fragment thereof.

4. A fusion protein as claimed in claim 2 or claim 3, wherein the fusion takes place at the hinge region.

5. A fusion protein as claimed in claims 1-4, wherein the protein fused to immunoglobulin is the extra-cellular portion of a membrane protein or parts thereof.

6. A fusion protein as claimed in claims 1-4, wherein the protein fused to immunoglobulin is the extracellular portion of thromboplastin or parts thereof.

7. A fusion protein as claimed in claims 1-4, wherein the protein fused to immunoglobulin is the extracellular portion of CD28 or parts thereof.

8. A fusion protein as claimed in claims 1-4, wherein the protein fused to immunoglobulin is the extracellular portion of a cytokine receptor or growth factor receptor or parts thereof.

9. A fusion protein as claimed in claim 8, wherein the protein fused to immunoglobulin is the extracellular portion of IL-4 receptor or parts thereof.

10. A fusion protein as claimed in claim 8, wherein the protein fused to immunoglobulin is the extracellular portion of IL-7 receptor or parts thereof.

11. A fusion protein as claimed in claim 8, wherein the protein fused to immunoglobulin is the extracellular portion of tumor necrosis factor receptor or parts thereof.

12. A fusion protein as claimed in claim 8, wherein the protein fused to immunoglobulin is the extracellular portion of G-CSF receptor or parts thereof.

13. A fusion protein as claimed in claim 8, wherein the protein fused to immunoglobulin is the extracellular portion of GM-CSF receptor or parts thereof.

14. A fusion protein as claimed in claim 8, wherein the protein fused to immunoglobulin is the extracellular portion of erythropoietin receptor or parts thereof.

15. A fusion protein as claimed in claims 1-4, wherein the protein fused to immunoglobulin is a non-membrane-bound soluble protein or parts thereof.

16. A fusion protein as claimed in claim 15, wherein the protein fused to immunoglobulin is a cytokine- or growth factor or parts thereof.

17. A fusion protein as claimed in claim 16, wherein the protein fused to immunoglobulin is erythropoietin or parts thereof.

18. A fusion protein as claimed in claim 16, wherein the protein fused to immunoglobulin is GM-CSF or G-CSF or parts thereof.

19. A fusion protein as claimed in claim 16, wherein the protein fused to immunoglobulin is interleukins IL-1 to IL-8 or parts thereof.

20. A process for preparing fusion proteins as claimed in any of claims 1-19, which comprises introducing the DNA coding for these constructs into a mammalian cell expression system and, after expression, purifying the produced fusion protein by affinity chromatography via the immunoglobulin portion.

21. The use of the fusion proteins as claimed in any of claims 1-19 for diagnosis.

22. The use of the fusion proteins as claimed in any of claims 1-19 for therapy.